Catalyst Pharmaceutical Partners Inc Stock in Q4 2017 Driven by Institutional Investors

April 21, 2018 - By Migdalia James

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Logo

Sentiment for Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX)

Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) institutional sentiment decreased to 1.97 in 2017 Q4. Its down -0.03, from 2 in 2017Q3. The ratio turned negative, as 59 institutional investors started new or increased stock positions, while 30 decreased and sold positions in Catalyst Pharmaceutical Partners Inc. The institutional investors in our partner’s database reported: 55.25 million shares, up from 34.72 million shares in 2017Q3. Also, the number of institutional investors holding Catalyst Pharmaceutical Partners Inc in their top 10 stock positions increased from 0 to 1 for an increase of 1. Sold All: 11 Reduced: 19 Increased: 25 New Position: 34.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $257.42 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and TouretteÂ’s disorder; and CPP-109 to treat TouretteÂ’s disorder.

The stock decreased 1.18% or $0.03 during the last trading session, reaching $2.51. About 371,938 shares traded. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 24.38% since April 21, 2017 and is uptrending. It has outperformed by 12.83% the S&P500.

Analysts await Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) to report earnings on May, 9. They expect $-0.06 earnings per share, 0.00 % or $0.00 from last year’s $-0.06 per share. After $-0.06 actual earnings per share reported by Catalyst Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Broadfin Capital Llc holds 4.54% of its portfolio in Catalyst Pharmaceuticals, Inc. for 7.10 million shares. Great Point Partners Llc owns 3.82 million shares or 2.55% of their US portfolio. Moreover, Tanaka Capital Management Inc has 2.29% invested in the company for 256,593 shares. The New York-based Consonance Capital Management Lp has invested 1.58% in the stock. Venbio Select Advisor Llc, a California-based fund reported 3.89 million shares.

Since January 1, 0001, it had 1 insider purchase, and 0 sales for $45,800 activity.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Ratings analysis reveals 100% of Catalyst Pharma’s analysts are positive. Out of 4 Wall Street analysts rating Catalyst Pharma, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $4.75 while the high is $8.0. The stock’s average target of $6.19 is 146.61% above today’s ($2.51) share price. CPRX was included in 6 notes of analysts from October 31, 2017. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, March 15. The stock has “Buy” rating by SunTrust on Monday, November 27. The rating was maintained by SunTrust on Tuesday, October 31 with “Buy”. The company was maintained on Friday, November 10 by H.C. Wainwright. Piper Jaffray maintained it with “Buy” rating and $8.0 target in Friday, December 1 report. The stock of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) earned “Buy” rating by Roth Capital on Wednesday, November 1.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.